Compare TG Therapeutics Inc (TGTX) vs ProShares UltraPro S&P500 (UPRO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs ProShares UltraPro S&P500 — how do they compare? TG Therapeutics Inc trades at $55.11 (market cap $8.16B), while ProShares UltraPro S&P500 trades at $156 (market cap $5.55B). The key difference: TG Therapeutics Inc is the larger of the two by market cap, and ProShares UltraPro S&P500 is more actively traded (2,078,694 versus 1,735,121). Which is the better fit depends on your goals — on Pluang, investors hold TG Therapeutics Inc for 16 Days and ProShares UltraPro S&P500 for 29 Days on average.
| TGTX | UPRO | |
|---|---|---|
Market Cap | $8.16B | $5.55B |
Volume | 1,735,121 | 2,078,694 |
Sector | Health | Leveraged / Inverse |
52-Week High | $59.06 | $157.66 |
52-Week Low | $26.94 | $89.29 |
Typical Hold Time | 16 Days | 29 Days |
Enterprise Value | $8.37B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
UPRO trades at $155.78, up 0.37% today, with a bullish technical signal from moving averages and neutral oscillators. The stock faces resistance near $157 and support at $151. Key financial ratios are unavailable in the provided data, limiting fundamental assessment. A dividend of $0.27 is scheduled for September 2026, indicating potential income for investors.
The outlook for UPRO is mixed, with technical strength offset by limited fundamental visibility. Risks include market volatility and concentration in top S&P 500 holdings. Upside depends on broader index performance, but investor skepticism amid high valuations may cap gains. Monitoring earnings growth and institutional sentiment is critical for direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About ProShares UltraPro S&P500
UPRO is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the S&P 500 Index. It is a tactical, high-conviction instrument designed for short-term traders to amplify bullish market moves, utilizing a daily reset mechanism that creates significant compounding effects and volatility risks over time.
Read more on UPRO →
